Leukemia and Lymphoma: Detection of Minimal Residual Disease

ISBN-13: 9780896039667 / Angielski / Twarda / 2002 / 257 str.

Martin H. Schreiber; Theodore F. Zipf; Dennis A. Johnston

Opis

In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for leukemias and lymphomas. They apply reverse transcription PCR (RT-PCR) to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for Non-Hodgkin's Lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.

Recenzje

"The book provides an excellent presentation of a wide spectrum of methods used in detection of MRD in ALL, CML, AML and Hodgkins lymphoma. It will certainly be of great help for all those, who are engaged in modern management of leukemias and lymphomas." -Neoplasma

Spis treści

Flow-Cytometry Methods for the Detection of Residual Leukemia Richard Ratei and Wolf-Dieter Ludwig Flow-Cytometry-Based Studies of Minimal Residual Disease in Children with Acute Lymphoblastic Leukemia Dario Campana PCR Methods for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia Geoffrey Neale Statistical Considerations in the Analysis of Minimal Residual Disease Dennis A. Johnston and Theodore F. Zipf The Application of Minimal Residual Disease Detection Methodology to the Clinical Decision-Making Process Theodore F. Zipf and Dennis A. Johnston Measurement of Minimal Residual Disease in Children Undergoing Allogeneic Stem Cell Transplant for Acute Lymphoblastic Leukemia John Moppett, Amos Burke, Christopher Knechtli, Anthony Oakhill, Colin Steward, and Nicholas J. Goulden Molecular Investigation of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia of B Lineage Letizia Foroni, Forida Y. Mortuza, and A. Victor Hoffbrand Investigation of Minimal Residual Disease in Acute Myeloid Leukemia by Immunophenotyping Jesús F. San Miguel, María B. Vidriales, and Alberto Orfao Minimal Residual Disease in Acute Myeloid Leukemia: RT-PCR-Based Studies of Fusion Transcripts Guido Marcucci and Michael A. Caligiuri Minimal Residual Disease in Acute Promyelocytic Leukemia Francesco Lo Coco and Daniela Diverio Minimal Residual Disease in Chronic Myelogenous Leukemia: Results of RT-PCR Detection of BCR-ABL Transcripts Nicholas C. P. Cross and Andreas Hochhaus Utility of PCR Assessment of Minimal Residual Disease After Stem Cell Transplantation in Non-Hodgkin's Lymphoma Angela M. Krackhardt and John G. Gribben Real-Time Polymerase Chain Reaction of Genomic DNA for Quantitation of t(14;18) Apostolia-Marie Tsimberidou, Yunfang Jiang, Richard J.Ford, Fernando Cabanillas, and Andreas H. Sarris Monitoring Follicular Lymphoma by Polymerase Chain Reaction Ming-Sheng Lee and Fernando Cabanillas Editors' Notes Index

Blurb

With the detection of the leukemias and lymphomas at levels almost four orders of magnitude below that obtainable by light microcopy, the groundwork has been laid for the development of reliable clinical tools and a redefinition of remission and relapse. In Leukemia and Lymphoma: Detection of Minimal Residual Disease, hands-on experts describe and discuss the minimal residual disease (MRD) methods they have successfully pioneered for these hematological cancers. The techniques range from the use of patient-specific immunophenotypes to identify residual leukemia in patients who are in remission, to a variety of PCR techniques for detecting residual disease and measuring its level. Reverse transcription PCR (RT-PCR) is applied to acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and acute promyelocytic leukemia (APL). Other PCR methods are used for non-Hodgkin's lymphoma and for the monitoring of follicular lymphoma. Additional chapters address the use of real-time quantitative PCR (RQ-PCR), the emergent method of choice, in patients with acute lymphoblastic leukemia (ALL), the evaluation of MRD techniques in clinical trials, and the application of flow cytometry techniques.
Comprehensive and innovative, Leukemia and Lymphoma: Detection of Minimal Residual Disease sets the stage for implementing the new standard detection and quantitation techniques as reliable tools for clinical decision-making, as well as for improved predictions and treatment outcomes.